AS/Spondyloarthritis
The last day was jammed with important reports and research including the late breaking abstracts.
A few things we know about opioids: use is common; it’s not efficacious in the treatment of spondyloarthritis; and, there is an opioid epidemic and its users are stigmatized. Abstract 0402 is a retrospective study that looked at patients with psoriatic arthritis or ankylosing spondylitis in the FORWARD databank. It sheds new light and leaves us with some food for thought
Strategies to identify patients with suspected inflammatory back pain in the general population is critical for timely and proper diagnosis.
Richard Conway RichardPAConway
2 years 7 months ago
Curtis et al. Primary non-adherence to csDMARDs and b/tsDMARDs in RA/PsA/SpA. Medicare and commerically-insured patients. 20-44%! of new prescriptions not filled by 6 months. Higher for csDMARDs than b/tsDMARDs @RheumNow #ACR22 Abstr#2199 https://t.co/Pwg6GKu7Gg https://t.co/wPF0pu1UDa
Robert B Chao, MD doctorRBC
2 years 7 months ago
Are your SpA pts planning on conceiving? Be careful with NSAID use
French study found age and NSAID use associated with longer time-to-conception.
Factors not associated: smoking, BASDAI score, DMARD use
#ACRBest Abs#1673 @RheumNow #ACR22 https://t.co/D63XTY7IB8
Eric Dein ericdeinmd
2 years 7 months ago
Ab1673 #ACR22: Time-to-Conception (T2C) in SpA
Prosp, observ
88F, 56 pregnancy
Subfertility in 45% F, T2C 16 mos
Risks: age, NSAID
Rx: NSAIDs (26%), steroids (9%), csDMARD (14%), biol (69%)
No control grp - Is it cause or correlate?
2020 Repro G/L rec d/c NSAID
@RheumNow #ACRBest https://t.co/e51XjhyH9u
Richard Conway RichardPAConway
2 years 7 months ago
Hamroun et al. Preconceptual NSAID use assoc impaired fertility in SpA, HR 3.01 for time-to-conception @RheumNow #ACR22 Abstr#1673 https://t.co/jresR9MfXF https://t.co/flyfJob9un
sheila RHEUMarampa
2 years 7 months ago
Dr S Hamroun shares their study data on factors assoc w/ time-to-conception in ♀️ w/ SpA:
❗Pre-conceptional NSAID use
❗Age
Thought-provoking.
Time to re-evaluate our NSAID prescribing practices for ♀️ SpA?
#ACR22 @RheumNow ABST#1673 https://t.co/cHED0I3vUe
sheila RHEUMarampa
2 years 7 months ago
Dr. Ogdie proposes a whole-patient care approach to the treat-to-target strategy in SpA with QoL as the most important target.
#ACR22 @Rheumnow @rheumarhyme @trishiemd https://t.co/GjLt2Nym3I
A new target for treatment in AxSpA is the dual inhibition of IL17A and IL17F (IL17A/F). IL17A is a key driver of the inflammation in the AxSpA and Psoriatic Arthritis (PsA). IL17A and its structurally related IL17F share biologic functional properties. Inhibition of both cytokines (IL17A/F) should result in a greater clinical benefit in AxSpA and PsA than IL17A inhibition alone.
Poster Hall